Genome Therapeutics Prices Stock Offering at $5.25 per Share | GenomeWeb

NEW YORK, Feb. 3 (GenomeWeb News) - Genome Therapeutics has set a price of $5.25 per share for the sale of up to 16.8 million shares of its common stock, the company said today.

The offering will fund the pending acquisition of Genesoft Pharmaceuticals, which was approved by the shareholders of both firms yesterday. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.